Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Amgen generated nearly $36.7 billion of FY 2025 revenue and about $7.7 billion of net income, while Iovance Biotherapeutics posted 60.6% revenue growth to roughly $263.5 million but remained unprofitable with a net loss near $391.0 million. The article favors Amgen as the steadier 2026 investment due to its earnings power, dividend, and durable portfolio, versus Iovance’s higher-risk growth profile and execution uncertainty. It also highlights ongoing regulatory, biosimilar, manufacturing, and litigation risks for Amgen, and manufacturing, reimbursement, and clinical-trial risks for Iovance.

Analysis

The market is effectively choosing between a cash-compounding platform and a clinical-optionality story. AMGN’s edge is not just earnings durability; it is that its free cash flow can fund both dividends and bolt-on portfolio defense while competitors like biosimilar players and wholesalers absorb more pricing friction. The hidden winner from that setup is often the distributor layer: MCK/COR/CAH retain bargaining power on volume, but CAH looks most exposed if payer pressure forces harsher rebate economics and slower inventory turns.

IOVA is a classic “good science, hard business” situation where the next 6-18 months matter far more than the headline growth rate. The market will likely underwrite the company based on commercialization credibility, not TAM, so any manufacturing hiccup, reimbursement delay, or trial readout miss can re-rate the stock sharply lower even if revenue keeps compounding. Conversely, a clean quarter with improving gross-to-net and treatment-center throughput could trigger a violent squeeze because expectations are still anchored to execution risk, not platform value.

The contrarian takeaway is that AMGN may be less “safe” than investors assume if patent cliffs and government pricing expand faster than pipeline replacement, while IOVA may be less fragile than bears assume because its balance sheet and cash runway buy time for adoption to inflect. The asymmetry favors expressing this as a relative-value trade rather than a simple outright long/short on quality versus speculation. Near-term catalysts are earnings guidance and reimbursement data over the next 1-2 quarters; the real inflection is whether IOVA can convert a single-product launch into a repeatable operating cadence by 2027.

Key Decisions for Investors

• Long AMGN / short IOVA as a 6-12 month pair trade: express quality vs execution risk with lower beta than an outright biotech short; target is modest multiple compression in IOVA if adoption or reimbursement stalls.
• Buy AMGN on a pullback only if the forward P/E stays near the low-teens: the setup is best when the market over-discounts patent/price risk, giving a defensible cash yield plus balance-sheet optionality.
• Use IOVA calls only as a catalyst trade around trial/quarterly updates: limited downside premium vs large upside if treatment-center throughput or reimbursement surprises positively over the next 1-2 quarters.
• Avoid CAH as the cleaner hedge in a pharma-pricing debate: the wholesalers are likely to absorb pressure before MCK/COR, but CAH has the weakest margin buffer if rebate intensity rises.
• If AMGN guidance is raised again while IOVA misses on launch metrics, add to the pair: the market will likely reward cash-flow certainty and punish commercialization slippage within one reporting cycle.